The Reproducible Evidence Practices to Enhance and Achieve Transparency (REPEAT) program chose the Aetion Evidence Platform (AEP) to do just that. In an aim to use quantifiable evidence to supplement or eliminate clinical trials, the REPEAT program will use the AEP as a scientifically validated platform to replicate and evaluate published healthcare data and real world evidence (RWE).
Reanalyzing done within the REPEAT program follows the goal of increasing confidence in using evidence from databases to set standards on transparent reporting to facilitate replicable findings.
According to Aetion, the evidence platform can analyze real-world data to determine medical needs. The FDA stated its interest in validating whether or not real-world evidence leads to the same regulatory decisions as clinical trials. Through the partnership with Aetion the REPEAT program will serve as part of this validation process.
This partnership will mean, “a seal of approval for Aetion as it replicates 150 studies from all corners of the world. That will be an important milestone for Aetion, and ultimately, an assurance of high-quality standards for real world evidence generation,” said Sebastian Schneeweiss co-founder and science lead at Aetion.
RWE has become an important demand in the pharmaceutical research industry. Earlier this month, Icon and Practice Fusion partnered to bring real world evidence into research being conducted by Icon.
Previous collaborations and innovations to incoporate RWE through data sharing have been done to provide new approaches to clinical trial design in order to eliminate unnecessary research and complete clinical trials more effectively and with a lower cost.
The selection of the AEP will build upon existing relationship Aetion has with Harvard Medical School (HMS), Brigham Women’s Hospital (BWH), and the US Food and Drug Administration (FDA).